spentitall wrote:
Niman,
Based purely on reading scientific articles, it seems to me that there was less understanding or agreement amongst the scientific community as to the implications of changes in HA 225. Furthermore, regardless of disagreements in how D225G is acquired (randomly or selectively), the potential effects of D225G seemed to be down played by the WHO.
In contrast it seems that some changes are generally well studied and accepted by the scientific community, such as H274Y conferring oseltamivir resistance. Another changes that I read quite a bit about last year was PB2 627. Last year some articles down played the severity of pH1N1 because it had E627, rather than K627. A published paper last year discussing the role of the SR polymorphism also discussed the effects in human (and swine) of E627K as though the effect of changes in this position are well accepted.
If E627K change keeps showing up, do you think the WHO's response will be more alarming as it seems the scientific community recognizes the significance of this change?
I don't see much of a change in the WHO response. All results are subject to interpretation as well as variation in testing. In UKraine 27/37 fatal lung samples had D225G/N, which is quite striking for a heterogeneous disease like influenza which usually does not kill, but WHO and the CDC still want to discount the result.
H274Y clearly knocks out Tamiflu and Peramivir, but WHO won't say much until it is fixed in pandemic H1N1, as happened to seasonal H1N1.
For E627K, it is more of a when than an if because all human seasonal flu has E627K. WHO can just say that H1N1 in the upper respirtaory tract is better than the lower respiratory tract, so E627K may make H1N1 more transmissible, but milder.